Community advisory boards (CABs) are community engagement platforms, comprised of treatment advocates and community leaders with lived experience to review the state of treatment research, contribute to research protocols, engage in the research and development process, and meet with industry and developers about cost, pricing, and access plans.
LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available
Four years after MPP and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers, generic G/P is not available anywhere. More
Long-Acting Technologies Trials Tracker for Hepatitis C, Opioid Use and Overdose Prevention Therapy, and Malaria
TAG released a trials tracker providing information on the development of long-acting HCV, malaria, and opioid use and overdose prevention therapy formulations. More
The HCV World CAB interacted with pharmaceutical and diagnostics companies that produce HCV treatment and tests to understand their access, licensing, and pricing strategies, particularly in high-burden, low- and middle-income countries.
Treatment activists held the first global LMIC-focused dialogue with pharmaceutical companies that produce HCV treatment, co-organized by TAG and the Asia Pacific Network of PLHA. More
The LAT CAB is a new cross-disease long-acting technologies (LAT) community advisory board focused on malaria, the hepatitis C virus, and latent TB infection.
LAT CAB reviews the state of treatment research, contributes to research protocols, and engages in the research and development process for long-acting technologies for malaria, HCV, and LTBI. More
Community Mobilization to Ensure Health Systems’ Readiness for Long-Acting Therapies - Webinar Recording Now Available Online
Webinar organized by Treatment Action Group, INPUD and AfroCAB. More